Takeda Pharmaceutical Company Ltd has announced that the European Commission has granted conditional marketing authorisation for Ninlaro (ixazomib) as a treatment in combination with Revlimid® and dexamethasone for relapsed and/or refractory myeloma patients who have received at least one previous line of treatment. This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use’s (CHMP) recommendation to approve Ninlaro based on data from the pivotal Phase III TOURMALINE-MM1 trial and means that it becomes the first oral proteasome inhibitor to be licensed in Europe.

 

Read full article